Daily Tax Report: State provides authoritative coverage of state and local tax developments across the 50 U.S. states and the District of Columbia, tracking legislative and regulatory updates,...
By Ryan Prete
Practitioners are skeptical that the growing trend among states to levy excise and sales taxes on opioids will curb the nationwide overdosing epidemic.
Six states—Kentucky, Minnesota, New Jersey, New York, Tennessee, and West Virginia—are mulling 12 measures proposing taxes on the distribution, production, and sales of the medication, according to the Healthcare Distribution Alliance, an organization representing primary pharmaceutical distributors.
Nine of the 12 bills were introduced or have advanced in the legislature this year. California, Mississippi, Oklahoma, and Virginia also are considering legislation.
The nation as a whole is witnessing a significant financial deficit from opioid overdoses. According to the National Institute on Drug Abuse, the amount paid for treatment of substance use disorders is only a small portion of the costs the disorders impose on society. The total cost of prescription opioid use disorders and overdoses in the United States was $78 billion in 2013. Of that, only 3.6 percent, or about $2.8 billion, was for treatment.
Richard Auxier, research associate at the Urban-Brookings Tax Policy Center at the Urban Institute, told Bloomberg Tax that he expects more states to migrate toward taxing those making or using the drug.
“We still need to understand if taxes directly placed on opioids is the best way to pay for treatment, but we can’t just be asking tax professionals, we need to hear from doctors and users,” Auxier said. “Dollars for treatment are obviously needed, but funding for every intervention program doesn’t necessarily need to be tied to the user. Opioid recovery programs can be installed today and instead tied to a general fund.”
While recent proposals to tax opioids have surfaced at the state level, U.S. Rep. Michelle Lujan Grisham (D-N.M.) introduced a like-minded federal bill in July 2017.
The Heroin and Opioid Abuse Prevention and Treatment Act of 2017 ( H.R. 3254) in part proposes a 1-cent-per-milligram tax on active opioid production, but the bill hasn’t moved since its introduction. The proposed tax would generate about $2 billion in annual revenue to expand access to substance abuse treatment and prevention programs, as well as fund new research on combating the opioid epidemic, according to a Grisham staff member.
“Our law enforcement agencies and health care providers are already overburdened and stretched to their limits. People are dying because they do not have the help they need. My bill will help fund the programs necessary to fight this epidemic,” Grisham told Bloomberg Tax in an email.
For now, states are leading the movement to tax opioids. But Liz Malm, director of strategic government relations and economist with the consulting firm MultiState Associates Inc., sees the campaign as a continuing but ill-fated trend.
“We do expect state legislatures to continue to explore myriad responses to the opioid epidemic, and funding for programs will certainly be part of that discussion,” Malm told Bloomberg Tax. “Many opioid tax proposals have been introduced, but thus far they have not been well thought out; generally, they would be difficult if not impossible to comply with or administer.”
Auxier said that states need to have goals for their proposed taxes. He explained that, following the theory of a soda and sugar tariff, a tax on the active opioid ingredient would reflect a plan to decrease consumption—while a tax on the volume of the medication would reflect a plan focused on raising revenue.
Still, Auxier said, taxing opioids is far more complicated than other “sin taxes” because there are multiple parties the burden could fall on, such as patients or insurance companies.
Auxier said that while there’s universal agreement that opioid abuse is a problem, a surcharge placed on distributors could easily be floated to consumers, potentially placing an economic burden on users of the drug.
“These proposals are very complex. While distributors and producers are the parties theoretically taxed, the additional cost could be passed onto consumers through price increases,” Auixer said. “Taxes placed directly on opioids could be harmful, potentially limiting the medication for people who need it.”
Auxier said that higher prices could push opioid users to seek out cheaper, more dangerous options, such as fentanyl, a powerful and widespread synthetic opioid. Fentanyl was a large contributor to the over 42,000 fatal opioid-related overdoses in 2016.
To contact the reporter on this story: Ryan Prete in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Ryan C. Tuck at email@example.com
Copyright © 2018 Tax Management Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)